Paolo Cravedi

List of Publications by Year
in descending order

213 papers	7,652 citations	71061 41 h-index	66879 78 g-index
225 all docs	225 docs citations	225 times ranked	9917 citing authors

#	Article	IF	Citations
1	Long-Term Outcome of Renal Transplantation from Older Donors. New England Journal of Medicine, 2006, 354, 343-352.	13.9	453
2	COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium. American Journal of Transplantation, 2020, 20, 3140-3148.	2.6	305
3	Dietary Intake Regulates the Circulating Inflammatory Monocyte Pool. Cell, 2019, 178, 1102-1114.e17.	13.5	254
4	The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nature Reviews Nephrology, 2010, 6, 319-330.	4.1	252
5	Rituximab in Idiopathic Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2012, 23, 1416-1425.	3.0	252
6	Mechanisms and Treatment of CKD. Journal of the American Society of Nephrology: JASN, 2012, 23, 1917-1928.	3.0	225
7	Regulatory T Cells and T Cell Depletion: Role of Immunosuppressive Drugs. Journal of the American Society of Nephrology: JASN, 2007, 18, 1007-1018.	3.0	224
8	Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome. Journal of the American Society of Nephrology: JASN, 2014, 25, 850-863.	3.0	199
9	Role of Remission Clinics in the Longitudinal Treatment of CKD. Journal of the American Society of Nephrology: JASN, 2008, 19, 1213-1224.	3.0	192
10	COVID-19 in kidney transplant recipients. American Journal of Transplantation, 2020, 20, 1941-1943.	2.6	184
11	Remodeling of the Immune Response With Aging: Immunosenescence and Its Potential Impact on COVID-19 Immune Response. Frontiers in Immunology, 2020, 11, 1748.	2.2	169
12	Titrating Rituximab to Circulating B Cells to Optimize Lymphocytolytic Therapy in Idiopathic Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 932-937.	2.2	150
13	A glomerulus-on-a-chip to recapitulate the human glomerular filtration barrier. Nature Communications, 2019, 10, 3656.	5.8	137
14	Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease. British Journal of Clinical Pharmacology, 2013, 76, 516-523.	1.1	133
15	Proteinuria should be used as a surrogate in CKD. Nature Reviews Nephrology, 2012, 8, 301-306.	4.1	124
16	Cutting Edge: Receptors for C3a and C5a Modulate Stability of Alloantigen-Reactive Induced Regulatory T Cells. Journal of Immunology, 2013, 190, 5921-5925.	0.4	112
17	The Human Pancreas as a Source of Protolerogenic Extracellular Matrix Scaffold for a New-generation Bioartificial Endocrine Pancreas. Annals of Surgery, 2016, 264, 169-179.	2.1	111
18	The Kidney Donor Profile Index (KDPI) of Marginal Donors Allocated by Standardized Pretransplant Donor Biopsy Assessment: Distribution and Association With Graft Outcomes. American Journal of Transplantation, 2014, 14, 2515-2525.	2.6	105

#	Article	IF	Citations
19	Immune Cell-Derived C3a and C5a Costimulate Human T Cell Alloimmunity. American Journal of Transplantation, 2013, 13, 2530-2539.	2.6	103
20	Mycophenolate Mofetil versus Azathioprine for Prevention of Chronic Allograft Dysfunction in Renal Transplantation: The MYSS Follow-Up Randomized, Controlled Clinical Trial. Journal of the American Society of Nephrology: JASN, 2007, 18, 1973-1985.	3.0	102
21	Recent Progress in the Pathophysiology and Treatment of FSGS Recurrence. American Journal of Transplantation, 2013, 13, 266-274.	2.6	97
22	Sirolimus Versus Cyclosporine Therapy Increases Circulating Regulatory T Cells, But Does Not Protect Renal Transplant Patients Given Alemtuzumab Induction From Chronic Allograft Injury. Transplantation, 2007, 84, 956-964.	0.5	94
23	Recurrence of FSGS after Kidney Transplantation in Adults. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 247-256.	2.2	94
24	COVID-19 and the kidney: what we think we know so far and what we donâ€™t. Journal of Nephrology, 2020, 33, 1213-1218.	0.9	91
25	Rituximab for Idiopathic Membranous Nephropathy: Who Can Benefit?. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 738-748.	2.2	83
26	Complement as a multifaceted modulator of kidney transplant injury. Journal of Clinical Investigation, 2014, 124, 2348-2354.	3.9	81
27	Predicting Cisplatin-Induced Acute Kidney Injury by Urinary Neutrophil Gelatinase-Associated Lipocalin Excretion: A Pilot Prospective Case-Control Study. Nephron Clinical Practice, 2010, 115, c154-c160.	2.3	79
28	COVID-19 and the Kidneys: An Update. Frontiers in Medicine, 2020, 7, 423.	1.2	79
29	Neutrophil Extracellular Traps Profiles in Patients with Incident Systemic Lupus Erythematosus and Lupus Nephritis. Journal of Rheumatology, 2020, 47, 377-386.	1.0	77
30	Efficacy and Safety of Rituximab Second-Line Therapy for Membranous Nephropathy: A Prospective, Matched-Cohort Study. American Journal of Nephrology, 2011, 33, 461-468.	1.4	67
31	A Peripheral Blood Gene Expression Signature to Diagnose Subclinical Acute Rejection. Journal of the American Society of Nephrology: JASN, 2019, 30, 1481-1494.	3.0	67
32	Complement component C5a induces aberrant epigenetic modifications in renal tubular epithelial cells accelerating senescence by Wnt4/Î²catenin signaling after ischemia/reperfusion injury. Aging, 2019, 11, 4382-4406.	1.4	66
33	Membranous Nephropathy Associated With IgG4-Related Disease. American Journal of Kidney Diseases, 2011, 58, 272-275.	2.1	64
34	Review: Ischemia Reperfusion Injuryâ€"A Translational Perspective in Organ Transplantation. International Journal of Molecular Sciences, 2020, 21, 8549.	1.8	64
35	Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. Journal of Hypertension, 2011, 29, 207-216.	0.3	62
36	Signaling through the Inhibitory Fc Receptor FcÎ³RIIB Induces CD8+ÂT Cell Apoptosis to Limit T Cell Immunity. Immunity, 2020, 52, 136-150.e6.	6.6	62

#	Article	IF	Citations
37	Evidence of potent humoral immune activity in COVID-19-infected kidney transplant recipients. American Journal of Transplantation, 2020, 20, 3149-3161.	2.6	54
38	Effects of Rituximab on Morphofunctional Abnormalities of Membranous Glomerulopathy. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1652-1659.	2.2	53
39	T-cell exhaustion correlates with improved outcomes in kidney transplant recipients. Kidney International, 2019, 96, 436-449.	2.6	49
40	Regenerative immunology: the immunological reaction to biomaterials. Transplant International, 2017, 30, 1199-1208.	0.8	48
41	Sirolimus for calcineurin inhibitors in organ transplantation: contra. Kidney International, 2010, 78, 1068-1074.	2.6	46
42	Immunosuppressive Effects of Erythropoietin on Human Alloreactive T Cells. Journal of the American Society of Nephrology: JASN, 2014, 25, 2003-2015.	3.0	46
43	Erythropoietin, a multifaceted protein with innate and adaptive immune modulatory activity. American Journal of Transplantation, 2019, 19, 2407-2414.	2.6	46
44	Kidney Failure Associates With T Cell Exhaustion and Imbalanced Follicular Helper T Cells. Frontiers in Immunology, 2020, 11, 583702.	2.2	46
45	Basiliximab Combined with Low-Dose Rabbit Anti-Human Thymocyte Globulin: A Possible Further Step toward Effective and Minimally Toxic T Cellâ€"Targeted Therapy in Kidney Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 546-554.	2.2	44
46	Erythropoietin Receptor-Mediated Molecular Crosstalk Promotes T Cell Immunoregulation and Transplant Survival. Journal of the American Society of Nephrology: JASN, 2017, 28, 2377-2392.	3.0	44
47	Rituximab in Primary Membranous Nephropathy: First-Line Therapy, Why Not?. Nephron Clinical Practice, 2015, 128, 261-269.	2.3	43
48	A step towards clinical application of acellular matrix: A clue from macrophage polarization. Matrix Biology, 2017, 57-58, 334-346.	1.5	42
49	Loss of decay-accelerating factor triggers podocyte injury and glomerulosclerosis. Journal of Experimental Medicine, 2020, 217, .	4.2	40
50	Immunologic monitoring in transplantation revisited. Current Opinion in Organ Transplantation, 2012, 17, 26-32.	0.8	39
51	Complement Regulation of T-Cell Alloimmunity. Seminars in Nephrology, 2013, 33, 565-574.	0.6	39
52	The role of renin angiotensin system inhibition in kidney repair. Fibrogenesis and Tissue Repair, 2010, 3, 7.	3.4	37
53	Effects of Add-on Fluvastatin Therapy in Patients with Chronic Proteinuric Nephropathy on Dual Renin-Angiotensin System Blockade. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1928-1938.	2.2	37
54	Prevention and Treatment of Diabetic Retinopathy: Evidence from Clinical Trials and Perspectives. Current Diabetes Reviews, 2011, 7, 190-200.	0.6	37

#	Article	IF	Citations
55	The marginal kidney donor. Current Opinion in Organ Transplantation, 2014, 19, 372-380.	0.8	35
56	Recurrence of IgA Nephropathy after Kidney Transplantation in Adults. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1247-1255.	2.2	35
57	Results from the IRoc-GN international registry of patients with COVID-19 and glomerular disease suggest close monitoring. Kidney International, 2021, 99, 227-237.	2.6	33
58	Recipient APOL1 risk alleles associate with death-censored renal allograft survival and rejection episodes. Journal of Clinical Investigation, 2021, 131, .	3.9	33
59	Preventing renal and cardiovascular risk by renal function assessment: insights from a cross-sectional study in low-income countries and the USA. BMJ Open, 2012, 2, bmjopen-2012-001357.	0.8	32
60	Effects of Antirejection Drugs on Innate Immune Cells After Kidney Transplantation. Frontiers in Immunology, 2019, 10, 2978.	2.2	32
61	T Cells and Acute Kidney Injury: A Two-Way Relationship. Frontiers in Immunology, 2020, 11, 1546.	2.2	30
62	COVID-19 in Children with Nephrotic Syndrome on Anti-CD20 Chronic Immunosuppression. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1494-1495.	2.2	30
63	Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial. Journal of the American Society of Nephrology: JASN, 2021, 32, 2652-2663.	3.0	30
64	Posttransplant peripheral blood donorâ€“specific interferon-Î³ enzyme-linked immune spot assay differentiates risk of subclinical rejection and de novo donor-specific alloantibodies in kidney transplant recipients. Kidney International, 2017, 92, 201-213.	2.6	29
65	Reduced mortality in COVID-19 patients treated with colchicine: Results from a retrospective, observational study. PLoS ONE, 2021, 16, e0248276.	1.1	29
66	Deep learning identified pathological abnormalities predictive of graft loss in kidney transplant biopsies. Kidney International, 2022, 101, 288-298.	2.6	28
67	Erythropoietin inhibits SGK1-dependent Th17 cell induction and Th17 cellâ€“dependent kidney disease. JCI Insight, 2019, 4, .	2.3	27
68	Monitoring T cell alloreactivity. Transplantation Reviews, 2015, 29, 53-59.	1.2	26
69	Analysis of OPTN/UNOS registry suggests the number of HLA matches and not mismatches is a stronger independent predictor of kidney transplant survival. Kidney International, 2018, 93, 482-490.	2.6	26
70	A Comprehensive Phenotypic and Functional Immune Analysis Unravels Circulating Antiâ€“Phospholipase A2 Receptor Antibody Secreting Cells in Membranous Nephropathy Patients. Kidney International Reports, 2020, 5, 1764-1776.	0.4	26
71	The spatially resolved transcriptional profile of acute T cellâ€“mediated rejection in a kidney allograft. Kidney International, 2022, 101, 131-136.	2.6	26
72	Report of Three Cases of Minimal Change Disease Following the Second Dose of mRNA SARS-CoV-2 COVID-19 Vaccine. Kidney International Reports, 2021, 6, 2523-2524.	0.4	26

#	Article	IF	Citations
73	Pretransplant transcriptomic signature in peripheral blood predicts early acute rejection. JCI Insight, 2019, 4, .	2.3	26
74	Rethinking Regenerative Medicine From a Transplant Perspective (and Vice Versa). Transplantation, 2019, 103, 237-249.	0.5	24
75	Cyclosporine Prolongs Delayed Graft Function in Kidney Transplantation: Are Rabbit Anti-Human Thymocyte Globulins the Answer?. Nephron Clinical Practice, 2005, 101, c65-c71.	2.3	23
76	Circulating Anti-PLA2R Autoantibodies to Monitor Immunological Activity in Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2011, 22, 1400-1402.	3.0	23
77	T Cell Expression of C5a Receptor 2 Augments Murine Regulatory T Cell (TREG) Generation and TREG-Dependent Cardiac Allograft Survival. Journal of Immunology, 2018, 200, 2186-2198.	0.4	23
78	DACH1 protects podocytes from experimental diabetic injury and modulates PTIP-H3K4Me3 activity. Journal of Clinical Investigation, 2021, 131, .	3.9	23
79	Sirolimus to replace calcineurin inhibitors? Too early yet. Lancet, The, 2009, 373, 1235-1236.	6.3	22
80	Prognostic Significance of Albuminuria in Patients With Renal Cell Cancer. Journal of Urology, 2003, 170, 1135-1137.	0.2	21
81	Intensified inhibition of renin-angiotensin system: A way to improve renal protection?. Current Hypertension Reports, 2007, 9, 430-436.	1.5	21
82	Old Donors for Kidney Transplantation: How Old?. Gerontology, 2011, 57, 513-520.	1.4	21
83	A large, international study on post-transplant glomerular diseases: the TANGO project. BMC Nephrology, 2018, 19, 229.	0.8	21
84	A catabolic state in a kidney transplant recipient with COVIDâ€19. Transplant International, 2020, 33, 1140-1141.	0.8	20
85	Which antihypertensive drugs are the most nephroprotective and why?. Expert Opinion on Pharmacotherapy, 2010, 11, 2651-2663.	0.9	19
86	Latest treatment strategies for membranous nephropathy. Expert Opinion on Pharmacotherapy, 2007, 8, 3159-3171.	0.9	18
87	Rituximab for membranous nephropathy and immune disease: less might be enough. Nature Clinical Practice Nephrology, 2009, 5, 76-77.	2.0	18
88	Complement and Complement Targeting Therapies in Glomerular Diseases. International Journal of Molecular Sciences, 2019, 20, 6336.	1.8	18
89	Noninvasive methods to assess the risk of kidney transplant rejection. Expert Review of Clinical Immunology, 2009, 5, 535-546.	1.3	17
90	Non-immune interventions to protect kidney allografts in the long term. Kidney International, 2010, 78, S71-S75.	2.6	17

#	Article	IF	Citations
91	Targeting the Renin Angiotensin System in Dialysis Patients. Seminars in Dialysis, 2011, 24, 290-297.	0.7	17
92	Trends in Immune Cell Function Assay and Donor-Specific HLA Antibodies in Kidney Transplantation: A 3-Year Prospective Study. American Journal of Transplantation, 2013, 13, 3215-3222.	2.6	17
93	Monitoring alloimmune response in kidney transplantation. Journal of Nephrology, 2017, 30, 187-200.	0.9	17
94	SHROOM3-FYN Interaction Regulates Nephrin Phosphorylation and Affects Albuminuria in Allografts. Journal of the American Society of Nephrology: JASN, 2018, 29, 2641-2657.	3.0	17
95	Making Procurement Biopsies Important Again for Kidney Transplant Allocation. Nephron, 2019, 142, 34-39.	0.9	17
96	Complement, a Therapeutic Target in Diabetic Kidney Disease. Frontiers in Medicine, 2020, 7, 599236.	1.2	17
97	Interferon-Î² acts directly on TÂcells to prolong allograft survival by enhancing regulatory T cell induction through Foxp3 acetylation. Immunity, 2022, 55, 459-474.e7.	6.6	17
98	Thrice-Weekly In-Center Nocturnal Hemodialysis: An Effective Strategy to Optimize Chronic Dialysis Therapy. International Journal of Artificial Organs, 2009, 32, 12-19.	0.7	16
99	Successes and Disappointments with Clinical Islet Transplantation. Advances in Experimental Medicine and Biology, 2010, 654, 749-769.	0.8	16
100	Effect of Trandolapril on Regression of Retinopathy in Hypertensive Patients with Type 2 Diabetes: A Prespecified Analysis of the Benedict Trial. Journal of Ophthalmology, 2010, 2010, 1-9.	0.6	16
101	HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents. Frontiers in Medicine, 2019, 6, 20.	1.2	16
102	Pretransplant Donor-specific IFNÎ³ ELISPOT as a Predictor of Graft Rejection: A Diagnostic Test Accuracy Meta-analysis. Transplantation Direct, 2019, 5, e451.	0.8	16
103	CyTOF-Enabled Analysis Identifies Class-Switched B Cells as the Main Lymphocyte Subset Associated With Disease Relapse in Children With Idiopathic Nephrotic Syndrome. Frontiers in Immunology, 2021, 12, 726428.	2.2	16
104	Natural antibody and complement activation characterize patients with idiopathic nephrotic syndrome. American Journal of Physiology - Renal Physiology, 2021, 321, F505-F516.	1.3	16
105	Non-Invasive Monitoring for Rejection in Kidney Transplant Recipients After SARS-CoV-2 mRNA Vaccination. Frontiers in Immunology, 2022, 13, 838985.	2.2	16
106	Early Proinflammatory Activation of Renal Tubular Cells by Normal and Pathologic IgG. Nephron Experimental Nephrology, 2005, 100, e77-e84.	2.4	15
107	Eosinophils Are Not Required for the Induction and Maintenance of an Alloantibody Response. American Journal of Transplantation, 2013, 13, 2696-2702.	2.6	15
108	Rapid Biolayer Interferometry Measurements of Urinary CXCL9 to Detect Cellular Infiltrates Noninvasively After Kidney Transplantation. Kidney International Reports, 2017, 2, 1186-1193.	0.4	15

#	Article	IF	Citations
109	Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. American Journal of Kidney Diseases, 2022, 79, 570-581.	2.1	15
110	Mycophenolate Mofetil Versus Azathioprine in Organ Transplantation. American Journal of Transplantation, 2009, 9, 2856-2857.	2.6	14
111	Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work?. Pharmaceuticals, 2010, 3, 1-9.	1.7	14
112	Immune-Monitoring Disease Activity in Primary Membranous Nephropathy. Frontiers in Medicine, 2019, 6, 241.	1.2	14
113	Effect of Timing and Complement Receptor Antagonism on Intragraft Recruitment and Protolerogenic Effects of Mesenchymal Stromal Cells in Murine Kidney Transplantation. Transplantation, 2019, 103, 1121-1130.	0.5	14
114	Management of Chronic Hyperkalemia in Patients With Chronic Kidney Disease: An Old Problem With News Options. Frontiers in Medicine, 2021, 8, 653634.	1.2	14
115	T-cell Exhaustion in Organ Transplantation. Transplantation, 2022, 106, 489-499.	0.5	14
116	Delayed Kinetics of IgG, but Not IgA, Antispike Antibodies in Transplant Recipients following SARS-CoV-2 Infection. Journal of the American Society of Nephrology: JASN, 2021, 32, 3221-3230.	3.0	14
117	Detecting, preventing and treating non-adherence to immunosuppression after kidney transplantation. CKJ: Clinical Kidney Journal, 2022, 15, 1253-1274.	1.4	14
118	Impact of preformed T-cell alloreactivity by means of donor-specific and panel of reactive T cells (PRT) ELISPOT in kidney transplantation. PLoS ONE, 2018, 13, e0200696.	1.1	13
119	Acute Kidney Injury (AKI) before and after Kidney Transplantation: Causes, Medical Approach, and Implications for the Long-Term Outcomes. Journal of Clinical Medicine, 2021, 10, 1484.	1.0	13
120	Differences in Humoral and Cellular Vaccine Responses to SARS-CoV-2 in Kidney and Liver Transplant Recipients. Frontiers in Immunology, 2022, 13, 853682.	2.2	13
121	Increased angiotensin-receptor blocking is not the first option. Nature Reviews Nephrology, 2009, 5, 367-368.	4.1	12
122	CD55 Deficiency and Protein-Losing Enteropathy. New England Journal of Medicine, 2017, 377, 1499-1500.	13.9	12
123	Achieving remission of proteinuria in childhood CKD. Pediatric Nephrology, 2017, 32, 321-330.	0.9	12
124	Rituximab in Membranous Nephropathy: Not All Studies Are Created Equal. Nephron, 2017, 135, 46-50.	0.9	12
125	Interleukin-1Î²-induced IRAK1 ubiquitination is required for TH-GM-CSF cell differentiation in T cell-mediated inflammation. Journal of Autoimmunity, 2019, 102, 50-64.	3.0	12
126	Rethinking clinical endpoints in kidney transplant trials. Current Opinion in Organ Transplantation, 2020, 25, 1-7.	0.8	12

#	Article	IF	Citations
127	Vaccines and Disease Relapses in Children with Nephrotic Syndrome. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 937-938.	2.2	12
128	Immunosuppressive Effects of the Traditional Chinese Herb Qu Mai on Human Alloreactive T Cells. American Journal of Transplantation, 2013, 13, 1159-1167.	2.6	11
129	Complement in Non-Antibody-Mediated Kidney Diseases. Frontiers in Medicine, 2017, 4, 99.	1.2	11
130	Switching renal transplant recipients to belatacept therapy: results of a real-life gradual conversion protocol. Transplant Immunology, 2019, 56, 101207.	0.6	11
131	Overexpression of PD-1 on T cells promotes tolerance in cardiac transplantation via ICOS-dependent mechanisms. JCI Insight, 2021, 6, .	2.3	11
132	History of Childhood Kidney Disease and Risk of Adult End-Stage Renal Disease. New England Journal of Medicine, 2018, 378, 1750-1752.	13.9	10
133	Criteria for Living Donation from Marginal Donors: One, No One, and One Hundred Thousand. Nephron, 2019, 142, 227-232.	0.9	10
134	The COVIDâ€19 pandemic: A community approach. Clinical Transplantation, 2020, 34, e14059.	0.8	10
135	COVID-19 in Patients with Glomerular Disease: Follow-Up Results from the IRoc-GN International Registry. Kidney360, 2022, 3, 293-306.	0.9	10
136	Treating the kidney to cure the heart. Kidney International, 2008, 74, S2-S3.	2.6	9
137	Low-density array PCR analysis of reperfusion biopsies: an adjunct to histological analysis. Nephrology Dialysis Transplantation, 2010, 25, 4077-4086.	0.4	9
138	Perioperative Minimal Induction Therapy: A Further Step toward More Effective Immunosuppression in Transplantation. Journal of Transplantation, 2012, 2012, 1-7.	0.3	9
139	A Multidrug, Antiproteinuric Approach to Alport Syndrome: A Ten-Year Cohort Study. Nephron, 2015, 130, 13-20.	0.9	9
140	Glomerular endothelial cell heterogeneity in Alport syndrome. Scientific Reports, 2020, 10, 11414.	1.6	9
141	Risk of COVIDâ€19 in young kidney transplant recipients. Results from a singleâ€center observational study. Clinical Transplantation, 2020, 34, e13889.	0.8	9
142	EPO in Patients With COVID-19: More Than an Erythropoietic Hormone. American Journal of Kidney Diseases, 2020, 76, 441.	2.1	9
143	Erythropoietin Reduces Auto- and Alloantibodies by Inhibiting T Follicular Helper Cell Differentiation. Journal of the American Society of Nephrology: JASN, 2021, 32, 2542-2560.	3.0	9
144	Antiâ€HLA and antiâ€SARSâ€CoVâ€2 antibodies in kidney transplant recipients with COVIDâ€19. Transplant International, 2021, 34, 596-599.	0.8	8

#	Article	IF	Citations
145	Erythropoietin administration expands regulatory T cells in patients with autoimmune hepatitis. Journal of Autoimmunity, 2021, 119, 102629.	3.0	8
146	Mycophenolate mofetil versus azathioprine in kidney transplant recipients on steroid-free, low-dose cyclosporine immunosuppression (ATHENA): A pragmatic randomized trial. PLoS Medicine, 2021, 18, e1003668.	3.9	8
147	Refractory focal segmental glomerulosclerosis in the adult: complete and sustained remissions of two episodes of nephrotic syndrome after a single dose of rituximab. BMJ Case Reports, 2014, 2014, bcr2014205507-bcr2014205507.	0.2	8
148	Role of monoclonal antibodies in the treatment of immune-mediated glomerular diseases. Nefrologia, 2014, 34, 388-97.	0.2	8
149	Mortality in solid organ transplant recipients with COVID-19: More than meets the eye. American Journal of Transplantation, 2022, 22, 1496-1497.	2.6	8
150	Alterations of Type IV Collagen Î± Chains in Patients with Chronic Acquired Glomerulopathies: mRNA Levels, Protein Expression and Urinary Loss. American Journal of Nephrology, 2007, 27, 129-137.	1.4	7
151	Intensified inhibition of renin-angiotensin system: A way to improve renal protection?. Current Hypertension Reports, 2009, 11, 118-124.	1.5	7
152	Low-Dose Rituximab for Posttransplant Recurrent Membranous Nephropathy. American Journal of Transplantation, 2010, 10, 1336.	2.6	7
153	Thrombotic Microangiopathies, Including Hemolytic Uremic Syndrome. , 2010, , 344-355.		7
154	Hypertension after kidney transplantation. Journal of Hypertension, 2011, 29, 2310-2311.	0.3	7
155	COVID-19 and the Kidney: A Worrisome Scenario of Acute and Chronic Consequences. Journal of Clinical Medicine, 2021, 10, 900.	1.0	7
156	Complement in Lupus: Biomarker, Therapeutic Target, or a Little Bit of Both?. Kidney International Reports, 2021, 6, 2031-2032.	0.4	7
157	Effect of disease progression on the podocyte cell cycle in Alport Syndrome. Kidney International, 2022, 101, 106-118.	2.6	7
158	The Gut and Kidney Crosstalk in Immunoglobulin A Nephropathy. Kidney360, 2022, 3, 1630-1639.	0.9	7
159	Does remission of renal disease associated with antihypertensive treatment exist?. Current Hypertension Reports, 2007, 9, 160-165.	1.5	6
160	Î²-cell transplantation for diabetes therapy â€“ Authors' reply. Lancet, The, 2008, 372, 29-30.	6.3	6
161	Circulating B Cells With Memory and Antibody-Secreting Phenotypes Are Detectable in Pediatric Kidney Transplant Recipients Before the Development of Antibody-Mediated Rejection. Transplantation Direct, 2019, 5, e481.	0.8	6
162	Totally tubular, dude: rethinking DKD pathogenesis in the wake of SGLT2i data. Journal of Nephrology, 2021, 34, 629-631.	0.9	6

#	Article	IF	Citations
163	Looking into the Graft without a Biopsy: Biomarkers of Acute Rejection in Renal Transplantation. Contributions To Nephrology, 2017, 190, 181-193.	1.1	6
164	Refractory Minimal Change Disease and Focal Segmental Glomerular Sclerosis Treated With Anakinra. Kidney International Reports, 2022, 7, 121-124.	0.4	6
165	More dissimilarities than affinities between DNAJB11-PKD and ADPKD. CKJ: Clinical Kidney Journal, 2022, 15, 1179-1187.	1.4	6
166	Islet transplantation: need for a time-out?. Nature Clinical Practice Nephrology, 2008, 4, 660-661.	2.0	5
167	New biologics in the treatment of rare glomerular diseases of childhood. Current Opinion in Pharmacology, 2017, 33, 27-33.	1.7	5
168	KIDNEY FAILURE STABILIZES AFTER AN INCREASE OVER 2 DECADES. Journal of Renal Care, 2007, 33, 100-104.	0.6	4
169	Lymphocyte depletion for kidney transplantation: back to the past?. Nature Clinical Practice Nephrology, 2008, 4, 534-535.	2.0	4
170	The Impact of Histologic Variants on FSGS Outcomes. International Scholarly Research Notices, 2014, 2014, 1-7.	0.9	4
171	Distinct peripheral blood molecular signature emerges with successful tacrolimus withdrawal in kidney transplant recipients. American Journal of Transplantation, 2020, 20, 3477-3485.	2.6	4
172	SARSâ€CoVâ€2 pandemic and the need for transplantâ€oriented trials. Transplant International, 2020, 33, 966-968.	0.8	4
173	Immune and gene expression profiling during tacrolimus to everolimus conversion early after liver transplantation. Human Immunology, 2021, 82, 81-88.	1.2	4
174	Long-term Apheresis in the Management of Patients With Recurrent Focal Segmental Glomerulosclerosis After Kidney Transplantation. Kidney International Reports, 2022, 7, 1424-1427.	0.4	4
175	Comment on: Robertson (2010) Islet Transplantation a Decade Later and Strategies for Filling a Half-Full Glass. Diabetes;59:1285-1291. Diabetes, 2010, 59, e13-e13.	0.3	3
176	Rituximab as First-Line Therapy in Severe Lupus Erythematosus with Neuropsychiatric and Renal Involvement: A Case-Report and Review of the Literature. Journal of Clinical Case Reports, 2017, 7, .	0.0	3
177	Immune responses towards bioengineered tissues and strategies to control them. Current Opinion in Organ Transplantation, 2019, 24, 582-589.	0.8	3
178	Pneumococcal Polysaccharide Vaccine Ameliorates Murine Lupus. Frontiers in Immunology, 2019, 10, 2695.	2.2	3
179	Preimplantation Histological Score Associates with 6-Month GFR in Recipients of Perfused, Older Kidney Grafts: Results from a Pilot Study. Nephron, 2021, 145, 137-149.	0.9	3
180	Complement in membranous nephropathy: what we thought we knew and what we really know. Kidney International, 2021, 100, 499-501.	2.6	3

#	Article	IF	Citations
181	Linking erythropoietin to Treg-dependent allograft survival through myeloid cells. JCI Insight, 2022, 7, .	2.3	3
182	Effect of a Novel Immunosuppressant, ST1959, on the Immune System and Renal Allograft Survival in Rats. Transplantation, 2005, 80, 231-236.	0.5	2
183	Optimizing Allocation of Kidneys from Older Donors. American Journal of Transplantation, 2011, 11, 182-182.	2.6	2
184	Harnessing T cell exhaustion to improve solid organ transplant outcomes. American Journal of Transplantation, 2021, 21, 1660-1661.	2.6	2
185	Erythropoietin in Lupus: Unanticipated Immune Modulating Effects of a Kidney Hormone. Frontiers in Immunology, 2021, 12, 639370.	2.2	2
186	Repository Corticotropin Injections Promote Clinical Remission and Regulatory T Cell Expansion in Membranous Nephropathy. Kidney International Reports, 2021, 6, 2491-2495.	0.4	2
187	Chemotherapy, targeted therapy and immunotherapy: Which drugs can be safely used in the solid organ transplant recipients?. Transplant International, 2021, 34, 2442-2458.	0.8	2
188	Preventing Coronavirus Disease 2019 in Kidney Transplant Recipients: Where Should We Begin?. Nephron, 2021, 145, 280-284.	0.9	2
189	ACTH action on podocytes: mystery solved?. American Journal of Physiology - Renal Physiology, 2016, 310, F1178-F1179.	1.3	1
190	Editorial: New perspectives to increase transplant numbers and survival. Current Opinion in Organ Transplantation, 2019, 24, 1-3.	0.8	1
191	Circulating B Cells, Plasma Cells, and Treg Associate with ANCA Levels in ANCA-associated Vasculitis. Kidney International Reports, 2021, 6, 496-500.	0.4	1
192	Prolonged Intradialytic Hypoxemia Is Associated With Functional Disturbances in Erythrocytes. Kidney International Reports, 2021, 6, 2702-2705.	0.4	1
193	Role of cyclooxygenase-2 in macrophage subsets during kidney repair. Kidney International, 2022, 101, 1084.	2.6	1
194	Regulatory T cells under scrutiny. Current Opinion in Organ Transplantation, 2004, 9, 301-306.	0.8	0
195	Current Status of Islet Transplantation. , 2014, , 583-598.		0
196	Dual Kidney Transplantation. , 2017, , 633-642.		0
197	Acute Cellular Rejection. , 2017, , 461-474.		0
198	FP062Complement activation mediates accelerated tubular and glomerular Inflammaging in Adriamycin (Adr)-Induced FSGS. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0

#	Article	IF	Citations
199	Handling immune-suppressive therapies during SARS-CoV-2 pandemic: insights from pediatric datasets. Journal of Nephrology, 2020, 33, 883-885.	0.9	0
200	FcÎ³RIIB, a new checkpoint to halt alloreactive memory T cells. American Journal of Transplantation, 2020, 20, 1967-1968.	2.6	0
201	Membranous nephropathy: setting the bar for hypothesis-driven, selective therapies in nephrology. Journal of Nephrology, 2021, 34, 561-563.	0.9	0
202	Ofatumumab or Rituximab for Children with Steroid- and Calcineurin Inhibitor -Dependent Nephrotic Syndrome - A Superiority Randomized Controlled Trial (OFA2). SSRN Electronic Journal, 0, , .	0.4	0
203	Hypertension and glomerular diseases: the importance of a holistic approach. Journal of Nephrology, 2021, 34, 1053-1055.	0.9	0
204	FC 131OFATUMUMAB OR RITUXIMAB FOR CHILDREN WITH STEROID-DEPENDENT NEPHROTIC SYNDROME. A RANDOMIZED CONTROLLED TRIAL. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0
205	Acute Renal Failure in Kidney Transplant Recipients. , 2009, , 1660-1665.		0
206	Nondiabetic Kidney Disease. , 2010, , 341-356.		0
207	Successes and Disappointments with Clinical Islet Transplantation. , 2015, , 1245-1274.		0
208	Acute Renal Failure in Kidney Transplant Recipients. , 2019, , 1279-1285.e3.		0
209	PD09-01â€ƒA GLOMERULUS ON A CHIP THAT RECAPITULATES THE PATHOPHYSIOLOGY OF THE HUMAN GLOMERULAR FILTRATION BARRIER. Journal of Urology, 2019, 201, .	0.2	0
210	Transplantation Immunobiology. , 0, , .		0
211	Transplantation Immunobiology. , 0, , .		0
212	Transplantation Immunobiology. , 0, , .		0
213	Kidney Immunology: embracing the complexity to advance the field. CKJ: Clinical Kidney Journal, 2022, 15, 366-367.	1.4	0